You just read:

Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients

News provided by

Asterias Biotherapeutics, Inc.

Aug 31, 2016, 06:30 ET